Dicerna Pharmaceuticals reported $-40244000 in EBIT for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Acceleron Pharma XLRN:US $ -63662000 59K
Agenus AGEN:US $ -66395000 25.02M
Alnylam Pharmaceuticals ALNY:US $ -146160000 40.09M
Amgen AMGN:US $ 2333M 204M
Arrowhead Research ARWR:US $ -31868000 3.64M
Biogen BIIB:US $ 1030.1M 12.3M
Bluebird Bio BLUE:US $ -240791000 9.95M
Dicerna Pharmaceuticals DRNA:US $ -40244000 11.14M
Exelixis EXEL:US $ 123.01M 127.62M
Gilead Sciences GILD:US $ 2262M 639M
GlaxoSmithKline GSK:LN 1.96B 281M
Immunogen IMGN:US $ -27369000 1.55M
Intercept Pharmaceuticals ICPT:US $ 511K 29.7M
IONIS PHARMACEUT IONS:US $ -72969000 19M
Karyopharm Therapeutics KPTI:US $ -49048000 3.32M
Lexicon Pharmaceuticals LXRX:US -17959000 2.88M
Macrogenics MGNX:US $ -40279000 11.01M
Merk MRK:US $ 3930M 332M
Mirati Therapeutics MRTX:US $ -164186000 31.76M
Pfizer PFE:US $ 6662M 905M
Regeneron Pharmaceuticals REGN:US $ 3347.2M 2234.5M
Ultragenyx Pharmaceutical RARE:US $ -82776000 23.79M